Ovarian Cancer
Korean HIPEC trial
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Mucinous Ovarian Carcinoma
GOG 241: Phase III Randomized Trial in Patients with Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.
Germ Cell Tumors of the Ovary
Granulosa Cell Tumors
Secondary Debulking Mini-Tutorial
Low-Grade Serous Ovarian Carcinoma
Relevant Study Summaries
GOG 281: Trametinib in recurrent low-grade serous
MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous
In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.
SOC-1
Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.